Steglatro (ertugliflozin) / Pfizer, Merck (MSD) - LARVOL DELTA

Successful Renal Replacement Therapy of Extreme Ertugliflozin and Alcohol IndUced Euglycaemic Ketoacidosis (PH 6.6) (DDG 2025) - "In the Months Preceding his Admission, The Patient Was Treated With A Combination of 15 Mg Ertugliflozin and 2x1000 mg Metformin per day. In our patient, crucial precautions to the use of sglt2 inhibitors were disregarded. The Extreme Acidosis (PH 6.6) What Striking and Has Never Been Reported Before in Sglt2 Inhibitor Related Edka - Nor in Sole Alcoholic Ketoacidosis. The Application of Early Renal Replacement Therapy to Effectively Manage the Extreme Acidosis was a Life Saving Measure."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Calcium Homeostasis: Where We Stand Now. (PubMed, Cells) - "Emerging data indicate that SGLT2i may lead to a rise of bone turnover markers, promoting a lower skeletal bone density and an increased fracture risk on murine models, but in real-world studies, results are controversial. Therefore, more clinical trials are needed to further clarify this topic, and the effects of SGLT2i on calcium homeostasis remain to date poorly understood."

Journal • Review • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Type 2 Diabetes Mellitus

Ertugliflozin attenuates atherosclerosis in nondiabetic ApoE-/- mice by upregulating ABCA1 and LDLR via the PPARγ/LXRα pathway. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "In summary, our results indicated that Ertugliflozin not only may reduce the area of atherosclerotic plaques in ApoE-/- mice but also upregulate ABCA1 and LDLR via the PPARγ/LXRα pathway to play a role in macrophages. Ertugliflozin upregulates ABCA1 and LDLR via the PPARγ/LXRα pathway to hinder the formation of macrophage-derived foam cells and reduce MOMA2 expression in atherosclerotic plaques (Fig. 5. Overall, our study reveals the potential medicinal value of Ertugliflozin in the treatment of AS, which provides a rationale for the use of Ertugliflozin in the clinical treatment of AS."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • ABCA1 • APOE • CD36 • LDLR • PPARG • SCARB1

Boldly Bradycardic: A Case Report of Brash Syndrome in the Setting of HFpEF (ATS 2025) - "Her home medication list included carvedilol, spironolactone, furosemide, empagliflozin, exogenous potassium, and recently prescribed ertugliflozin...ACLS protocol was initiated for hypotension, including one round of epinephrine...Standard hyperkalemia treatments of calcium, insulin, and albuterol are effective if BRASH is caught early enough. AV-blocking agents and medications that increase the risk of hyperkalemia should be avoided to prevent recurrence."

Case report • Clinical • Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Fatigue • Gastrointestinal Disorder • Hypertension • Hypotension • Immunology • Metabolic Disorders • Renal Disease • Respiratory Diseases • Type 2 Diabetes Mellitus

The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases. (PubMed, Curr Neurol Neurosci Rep) - "Canagliflozin and empagliflozin are associated with reduction in major adverse cardiovascular events (MACE). Dapagliflozin did not reduce the rate of MACE but is associated with reduction in heart-failure related death and hospitalization and has the potential to decrease dementia risk. Ertugliflozin decreases rates of hospitalization related to heart failure however it was non-inferior to placebo in reducing MACE...Antihyperglycemic therapy should be tailored to patients' circumstances. SGLT2i treatment should be considered in patients with type 2 diabetes and established or high-risk cardiovascular disease, heart failure, or chronic kidney disease, to reduce the overall cerebro-cardiovascular and renal risks."

Journal • Review • Alzheimer's Disease • Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Dementia • Diabetes • Heart Failure • Hematological Disorders • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • Vascular Neurology

A RETROSPECTIVE ANALYSIS OF SGLT2 INHIBITORS AND ERYTHROCYTOSIS (EHA 2025) - "The most used SGLT2i was empagliflozin ( N=27), followed by dapagliflozin (N=3), ertugliflozin ( N=3), and canagliflozin ( N=1). In our study, we observed significant increases in hemoglobin (Hb) and hematocrit (Hct) levels from baseline to peak with SGLT2i therapy, with no reported thrombosis during treatment. Additionally, Hb levels decreased after discontinuation of SGLT2i therapy. Given these findings, and the increasing use of SGLT2 inhibitors, larger-scale studies are needed to further investigate the erythrocytosis effects of these drugs, to prevent unnecessary invasive and costly testing."

Retrospective data • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Disorders • Metabolic Disorders • Nephrology • Renal Disease • Thrombosis • Type 2 Diabetes Mellitus • JAK2

Heart Failure Treatment in Underserved Populations: A Comprehensive Analysis of Sacubitril/Valsartan and Sodium-Glucose Transporter 2 Inhibitor (SGLT2i) Prescription Trends at a Safety Net Hospital. (PubMed, Cureus) - "Results Of the 769 patients prescribed sacubitril/valsartan, 497 (64.6%) were prescribed the 24 mg/26 mg dose, 193 patients (25.1%) received the 49 mg/51 mg dose, and 79 patients (10.3%) were on the 97 mg/103 mg dose...Regarding SGLT2is, 2,287 patients were prescribed these medications: 343 patients were prescribed dapagliflozin (188 at the 5 mg dose and 155 at the 10 mg dose); one patient received ertugliflozin at the 5 mg dose; 634 patients were prescribed canagliflozin (404 at the 100 mg dose, 173 at the 300 mg dose, 40 at the 50 mg dose with metformin combination, and 17 at the 150 mg dose with metformin combination); and 1,309 patients were prescribed empagliflozin (972 at the 10 mg dose, 333 at the 25 mg dose, two at the 5 mg dose with metformin combination, and two at the 12.5 mg dose with metformin combination)...Conclusions Robust evidence supports the use of sacubitril/valsartan and SGLT2is in HF, with both also proving effective for treating other diseases..."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=34 | Recruiting | Sponsor: Amsterdam UMC, location VUmc

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Understanding How Formulary Pricing Models Shape Medication Accessibility and Financial Burden for Aging Populations (ISPOR 2025) - "Alzheimer’s treatments like galantamine and rivastigmine were often in higher tiers, raising out-of-pocket costs. COPD medications, including Symbicort and Trelegy Ellipta, despite preferred tier placement, posed financial challenges. Rheumatoid arthritis drugs, particularly Humira in Tier 5, imposed heavy costs. Similarly, ischemic heart disease and type 2 diabetes medications like Eliquis and Steglatro often appeared in higher tiers, worsening adherence issues... Older patients in the U.S., particularly those dealing with chronic illnesses, still encounter significant financial pressure due to increasing prescription prices. Although initiatives such as the Inflation Reduction Act provide some assistance, the strain persists, leading to low compliance and adverse health results. The results highlight the urgent necessity for strong policies to improve price transparency, increase access to affordable generics, and stop the unjust classification of generics in higher..."

Clinical • Pricing • Alzheimer's Disease • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Heart Failure • Immunology • Inflammatory Arthritis • Metabolic Disorders • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) (clinicaltrials.gov) - P3 | N=165 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Pediatrics • Type 2 Diabetes Mellitus

Revealing water structure modification by a sodium-glucose cotransporter-2 inhibitor-type antidiabetic drug with D-(+)-glucose in aqueous media. (PubMed, Phys Chem Chem Phys) - "In this work, volumetric, acoustic, viscometric, and photon correlation spectroscopic studies of an antidiabetic drug, ertugliflozin L-pyroglutamic acid (E.L-PGA) have been performed in aqueous medium in absence and presence of D-(+)-glucose...For both binary and ternary systems, ΔG, ΔH, and ΔS vary from 8.4 to 9.2 kJ mol-1, 12 to 17 kJ mol-1, and 12 to 26 J mol-1, respectively. These results offer valuable insights into the molecular-level interactions of E.L-PGA with D-(+)-glucose under different perturbations and help understand pharmacological action and potential contraindications to open new avenues for the development of efficacious antidiabetic drugs."

Journal

Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. (PubMed, Diabetes Res Clin Pract) - "Arms included canagliflozin (n = 2), dapagliflozin (n = 6), empagliflozin (n = 6), ertugliflozin (n = 1), ipragliflozin (n = 1), sotagliflozin (n = 1), placebo (n = 13), and standard of care (n = 4). In patients with HF and T2DM, SGLT2i class effects include ACM, ACH, and HHF reduction. Among SGLT2i, canagliflozin showed greatest ACM, CVD, and HHF benefit."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in Gαq-mice. (PubMed, J Mol Cell Cardiol Plus) - "Our goal was to test the effect of the SGLT2 inhibitor ertugliflozin on mitochondrial gene expression and function in myocardium and isolated mitochondria from non-diabetic mice with dilated cardiomyopathy due to cardiac-specific over-expression of Gαq...In Gαq mice, marked suppression of myocardial gene programs for oxidative phosphorylation and fatty acid metabolism was reversed by ERTU. The SGLT2 inhibitor ERTU corrected the expression of myocardial gene programs for oxidative phosphorylation and fatty acid metabolism, and was associated with increased production of ATP, decreased release of mitochondrial ROS, and amelioration of the consequences of mitochondrial dysfunction on myocardial structure and function."

Journal • Preclinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Metabolic Disorders

Prolonged Euglycemic Diabetic Ketoacidosis in the Setting of Ertugliflozin Use (ENDO 2025) - "Due to a negative fluid balance, cortisol and epinephrine levels are increased, further increasing insulin resistance and promoting ketosis, independent of insulin and glucagon levels. However, it is proposed the higher rates of fixed dose insulin infusion supported by dextrose may be needed, as in our case, rather than lower and variable insulin dosing that is the standard of care for DKA in order for rapid and successful management.*. .*"

Addiction (Opioid and Alcohol) • Cardiovascular • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Pain • Pancreatitis • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

SGLT2 inhibitors Use in Kidney Disease: What Did We Learn? (PubMed, Am J Physiol Endocrinol Metab) - "Post marketing cardiovascular outcome trials (CVOT) have demonstrated improved cardiovascular outcomes with use of sodium-glucose cotransporter-2 inhibitors SGLT2i) like canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin in patients with type 2 diabetes mellitus (T2DM), Similarly, secondary analysis of CVOT and renal outcome trials with the use of SGLT2i in patients without T2DM showed improved renal function and albuminuria. Based on our research of published literature, we present a review and propose, consideration of SGLT2i in non-diabetic kidney disease for long term cardiovascular and renal benefit (1). We will highlight relevant translational studies to propose a possible cell-based mechanism for cardiovascular benefits noted secondary to use of SGLT2i."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Identification and investigation of hits targeting the N-methyl-D-aspartate receptor via drug repurposing: A plausible approach for anti-Alzheimer drug discovery. (PubMed, J Mol Graph Model) - "The high throughput virtual screening (HTVS) followed by molecular docking and molecular mechanics studies enabled us to identify two drugs, Ertugliflozin (Dock Score: -9.43 kcal/mol, MMGBSA: -104.50 kcal/mol) and Selpercatinib (Dock Score: 8.11 kcal/mol, MMGBSA: 83.62 kcal/mol), with a high affinity towards the NMDAR. The work is further supported by strong literature evidence that concludes the impact of antidiabetic molecules on AD progression, along with the evidence that Ertugliflozin possesses efficacy against AD with unequivocal evidence on the biological target and the mechanism. Further work, however, is required to establish this association in the in vivo or suitable model that could mimic the AD microenvironment as a part of future research."

Journal • Alzheimer's Disease • CNS Disorders

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. (PubMed, Front Pharmacol) - "According to the SUCRA based relative ranking of treatments, Empagliflozin was the most effective in reducing HbA1c and DBP...Liraglutide was the most effective in reducing LDL-C. Bexagliflozin, Canagliflozin were the most effective in reducing SBP and body weight. Finerenone had the lowest incidence of urinary tract infection, Hypoglycemia was the lowest in the Luseogliflozin group. Ertugliflozin was the least likely to cause acute kidney injury...SGLT-2 inhibitors had a preferential glucose-lowering and weight-loss function, GLP-1 receptor agonists had a preferential lowering of LDL-C and blood glucose, and Finereone significantly reduced SBP compared with PBO. Systematic Review Registration: PROSPERO, CRD42024571544."

Clinical • Journal • Retrospective data • Review • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure. (PubMed, Physiol Rep) - "Changes in other neurohormones, sympathetic activity, kidney, and systemic hemodynamics did not differ compared to placebo. Our findings suggest that SGLT2 inhibition shifts systemic volume toward a state of euvolemia, potentially lowering the risk of worsening heart failure."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

Combination therapy with vitamin E and ertugliflozin in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a randomized clinical trial. (PubMed, Ir J Med Sci) - "The ertugliflozin and vitamin E combination is a very effective treatment for patients with NAFLD and T2DM. It improves hepatic steatosis and metabolic indicators. Exploration is required for combination therapy in order to assess the prolonged efficacy and safety of the treatment."

Clinical • Journal • Diabetes • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

EFFECT OF SGLT2I ON LEFT VENTRICULAR EJECTION FRACTION AND INFARCT SIZE IN ANIMAL MODELS OF MYOCARDIAL INFARCTION: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS - Claudia Baez-Diaz (ACC 2025) - "We performed subgroup analysis looking at the influence of each individual gliflozin, diabetic status of the subjects (Y/N) and animal species (rodents versus swine). Eligible studies used empagliflozin, dapagliflozin, canagliflozin, ertugliflozin or sotagliflozin. The use of SGLT2i in animal models of MI and IR seems to have a beneficial effect on cardiac function irrespectively of the SGLT2i used as reflected by an improvement in EF, but dapagliflozin could be more effective in decreasing infarct size than empagliflozin in the experimental setting."

Preclinical • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Reperfusion Injury

Use of Sodium-Glucose Co-Transporter-2 Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B, Type 2 Diabetes, and Varying Fibrosis Status (APASL 2025) - "Patients with T2D and CHB who received SGLT-2i (empagliflozin, dapagliflozin, canagliflozin or ertugliflozin) or sulfonylureas between 2015 and 2021 were enrolled from Hong Kong and all patients were followed from the first prescription of study medication till 2022. In this population-based cohort study, use of SGLT-2i, compared with sulfonylureas, decreased the risk of HCC among individuals with T2D and CHB especially in more severe liver fibrosis, suggesting a potential chemopreventive role of SGLT-2i in patients with both chronic diseases. Table and Figure:Figure 1.Table. Association between SGLT-2i use and the risk of hepatocellular carcinoma in patients with type 2 diabetes and chronic hepatitis B. *adjusted for demographic data (age and sex), lifestyle factors (alcohol, smoking, and body mass index), comorbidities (hypertension, hyperlipidemia, heart failure, coronary heart disease, stroke, atrial fibrillation, and chronic kidney disease), HBV medications..."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Fibrosis • Heart Failure • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Hypertension • Immunology • Infectious Disease • Liver Cirrhosis • Metabolic Disorders • Nephrology • Oncology • Renal Disease • Solid Tumor • Type 2 Diabetes Mellitus

Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond. (PubMed, Curr Drug Res Rev) - "This class includes five drugs, including canagliflozin, ertugliflozin, sotagliflozin, dapagliflozin, and empagliflozin. In general, SLGT2 inhibitors are an efficient diabetes treatment with strong cardiovascular and renal protection and a favourable safety overview. This review sought to summarise the safety overview of commercially available SGLT2 inhibitors."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypoglycemia • Infectious Disease • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Type 2 Diabetes Mellitus

EFFECT OF ERTUGLIFLOZIN ON KIDNEY OUTCOMES IN ADULTS WITH AND WITHOUT AN INTERVAL CARDIOVASCULAR EVENT - A SECONDARY ANALYSIS OF VERTIS CV - Ayodele Odutayo (ACC 2025) - P3 | "In VERTIS CV, ERTU reduced kidney disease progression vs PBO with the suggestion of greater benefit following an ICVE. These data lend support to the concept of continuing SGLT2is following an ICVE for kidney protection."

Clinical • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Sodium-glucose co-transporters (SGLT2) inhibitors prevent lipid droplets formation in vascular inflammation or lipid overload by SGLT2-independent mechanism. (PubMed, Biomed Pharmacother) - "This is the first report demonstrating that SGLT2-I prevent the formation of LDs in the vasculature. Empagliflozin downregulates LDs formation in vascular inflammation or lipid overload via an SGLT2-independent mechanism. Empagliflozin's protective effects involve the NHE1/PKC/NOX pathway in the TNF response but not in the OA response."

Journal • Diabetes • Inflammation • Metabolic Disorders • Oncology • ICAM1

Ertu-NASH: Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD (clinicaltrials.gov) - P4 | N=164 | Recruiting | Sponsor: Getz Pharma | Trial primary completion date: Mar 2024 ➔ Nov 2025 | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2024 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Diabetes • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus